Featured on Today.com, Dr. Joseph Dayan, director of The Institute for Lymphatic Surgery and Innovation, is at the forefront of a promising new approach to treating lymphedema in breast cancer survivors. Known for his expertise in lymphatic surgery, Dr. Dayan is now investigating the off-label use of GLP-1 medications—commonly prescribed for weight loss and Type 2 diabetes—to manage this often debilitating condition.
Calling the early results “the most exciting thing” in his 20-year clinical career outside the operating room, Dr. Dayan has treated about two dozen patients with these medications and reported notable improvements. He emphasizes that the benefits may go beyond weight loss, potentially reducing inflammation and improving lymphatic function.
Dr. Dayan is also leading the first prospective study on GLP-1 therapy for lymphedema, aiming to enroll 110 patients. His work could redefine treatment strategies for the estimated 40% of breast cancer survivors affected by the condition.
Read the complete article here: